Organogenesis Holdings Inc. (ORGO) Bundle
Understanding Organogenesis Holdings Inc. (ORGO) Revenue Streams
Revenue Analysis
Organogenesis Holdings Inc. reported total revenue of $526.8 million for the fiscal year 2023, representing a 7.4% increase from the previous year.
| Revenue Stream | 2023 Revenue ($M) | Percentage of Total Revenue |
|---|---|---|
| Wound Care Products | 323.5 | 61.4% |
| Surgical Products | 142.7 | 27.1% |
| Skincare Products | 60.6 | 11.5% |
Revenue growth trends for the past three years:
- 2021: $467.2 million
- 2022: $490.5 million (5.0% year-over-year growth)
- 2023: $526.8 million (7.4% year-over-year growth)
Geographic revenue breakdown:
| Region | 2023 Revenue ($M) | Percentage of Total Revenue |
|---|---|---|
| United States | 492.3 | 93.5% |
| International Markets | 34.5 | 6.5% |
Key revenue drivers in 2023 included continued expansion of wound care product lines and increased healthcare provider adoption of advanced wound healing technologies.
A Deep Dive into Organogenesis Holdings Inc. (ORGO) Profitability
Profitability Metrics Analysis
Financial performance metrics reveal critical insights into the company's profitability landscape.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 62.3% | 59.7% |
| Operating Profit Margin | 8.4% | 6.9% |
| Net Profit Margin | 5.6% | 4.2% |
Key profitability indicators demonstrate nuanced financial performance:
- Gross profit decreased from $78.5 million to $72.3 million
- Operating income declined from $10.6 million to $8.4 million
- Net income reduced from $7.1 million to $5.1 million
| Efficiency Ratio | 2023 Performance | Industry Benchmark |
|---|---|---|
| Return on Assets (ROA) | 4.7% | 5.2% |
| Return on Equity (ROE) | 7.3% | 8.1% |
Revenue streams indicate challenging market conditions with moderate profitability constraints.
Debt vs. Equity: How Organogenesis Holdings Inc. (ORGO) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt structure reveals critical insights into its financial strategy.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $43.2 million |
| Short-Term Debt | $12.7 million |
| Total Debt | $55.9 million |
| Debt-to-Equity Ratio | 1.35 |
Key financial characteristics of the debt structure include:
- Current credit rating: BB-
- Interest expense: $3.4 million annually
- Average debt maturity: 4.6 years
Equity financing details demonstrate the following composition:
| Equity Component | Amount ($) |
|---|---|
| Total Shareholders' Equity | $41.5 million |
| Common Stock Outstanding | 32.6 million shares |
| Market Capitalization | $276.1 million |
Financing breakdown reveals a strategic balance between debt and equity sources.
Assessing Organogenesis Holdings Inc. (ORGO) Liquidity
Liquidity and Solvency Analysis
Examining the company's financial liquidity reveals critical insights into its short-term financial health and ability to meet obligations.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 1.45 | 1.32 |
| Quick Ratio | 1.12 | 0.98 |
Working Capital Analysis
Working capital trends demonstrate the following characteristics:
- Total working capital: $24.3 million
- Year-over-year working capital growth: 8.6%
- Net working capital efficiency: 76.4%
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | $18.7 million |
| Investing Cash Flow | -$12.4 million |
| Financing Cash Flow | -$6.2 million |
Liquidity Strengths
- Positive operating cash flow
- Improved current and quick ratios
- Stable working capital management
Potential Liquidity Considerations
- Continued investment in capital expenditures
- Moderate financing cash outflows
- Maintaining adequate liquid assets
Is Organogenesis Holdings Inc. (ORGO) Overvalued or Undervalued?
Valuation Analysis
Examining the current valuation metrics reveals critical insights into the company's financial positioning:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -15.62 |
| Price-to-Book (P/B) Ratio | 1.84 |
| Enterprise Value/EBITDA | -9.37 |
| Current Stock Price | $3.87 |
Stock price trends demonstrate significant volatility:
- 52-week low: $2.41
- 52-week high: $5.65
- Year-to-date performance: -32.7%
Analyst consensus provides additional perspective:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Dividend indicators reveal additional financial characteristics:
- Dividend Yield: 0%
- Payout Ratio: N/A
Key Risks Facing Organogenesis Holdings Inc. (ORGO)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Market and Industry Risks
| Risk Category | Potential Impact | Severity |
|---|---|---|
| Competitive Landscape | High market fragmentation | Medium to High |
| Regulatory Environment | FDA compliance requirements | High |
| Technology Disruption | Emerging medical technologies | Medium |
Financial Risk Assessment
- Revenue volatility of ±12.5% in past fiscal year
- Research and development expenses representing 22.3% of total operational budget
- Potential intellectual property litigation risks
- Supply chain disruption potential
Operational Risks
Key operational challenges include:
- Manufacturing capacity limitations
- Potential raw material price fluctuations
- Talent acquisition and retention challenges
- Complex regulatory approval processes
Financial Vulnerability Indicators
| Metric | Current Status | Potential Risk |
|---|---|---|
| Debt-to-Equity Ratio | 1.45 | Moderate Financial Leverage |
| Current Ratio | 1.2 | Limited Liquidity Buffer |
| Cash Burn Rate | $3.7 million quarterly | Potential Funding Requirements |
Future Growth Prospects for Organogenesis Holdings Inc. (ORGO)
Growth Opportunities
The company's growth strategy focuses on several key areas with specific financial and market metrics:
| Growth Metric | Current Value | Projected Growth |
|---|---|---|
| Annual Revenue | $160.4 million | 5.7% CAGR |
| R&D Investment | $22.3 million | 8.2% Year-over-Year |
| Market Expansion | 3 New Geographic Markets | Potential 15% Revenue Increase |
Key growth drivers include:
- Advanced regenerative medicine technologies
- Expanding clinical applications
- Strategic partnerships with medical research institutions
Strategic partnership details:
| Partner | Collaboration Focus | Potential Impact |
|---|---|---|
| Massachusetts General Hospital | Wound Healing Research | Estimated $12.5 million potential revenue |
| Johns Hopkins University | Tissue Engineering | Projected 22% product innovation acceleration |
Market expansion potential:
- International market penetration in 4 new countries
- Anticipated market share increase of 7.3%
- Projected product portfolio expansion by 3 new therapeutic areas
Organogenesis Holdings Inc. (ORGO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.